US Broker Ratings

Incyte Corporation (INCY) Stock Analysis: Growth Potential with a 5.75% Upside and Strong Revenue Growth

Investors looking for opportunities in the biotechnology sector might find Incyte Corporation (NASDAQ: INCY) particularly compelling. With a market capitalization of $20.15 billion, Incyte has positioned itself as a prominent..

Viatris Inc. (VTRS) Stock Report: Navigating the Healthcare Giant’s 3.22% Dividend Yield and Revenue Growth

Viatris Inc. (NASDAQ: VTRS), a notable player in the healthcare sector, continues to capture investor attention with its substantial market presence and intriguing financial indicators. As a key entity in..

Align Technology, Inc. (ALGN)

⚠️ No article content returned.

..

Revolution Medicines, Inc. (RVMD) Stock Analysis: Navigating the Highs of a 27% Potential Upside

Revolution Medicines, Inc. (RVMD), a prominent player in the biotechnology sector, is capturing the attention of investors with its ambitious foray into precision oncology. Headquartered in Redwood City, California, Revolution..

Genmab A/S (GMAB) Stock Analysis: A 27% Upside Potential in the Biotech Arena

Genmab A/S (NASDAQ: GMAB), a prominent player in the biotechnology sector, has caught the attention of investors with its robust pipeline and strategic collaborations. Headquartered in Copenhagen, Denmark, Genmab focuses..

Haleon plc (HLN) Stock Analysis: A Solid Healthcare Player with 7.75% Upside Potential

Haleon plc (HLN), a formidable entity in the healthcare sector, continues to capture investor attention with its robust market presence and a promising 7.75% potential upside. With a market capitalization..

The Cooper Companies, Inc. (COO) Stock Analysis: Exploring a Potential 8.76% Upside in Healthcare Innovation

The Cooper Companies, Inc. (NYSE: COO), a prominent player in the healthcare sector, has piqued investor interest with a potential upside of 8.76%, according to recent analyst ratings. With a..

Eli Lilly (LLY) Stock Analysis: Exploring Its 15% Upside Potential and Robust Revenue Growth

Eli Lilly and Company (NYSE: LLY), a stalwart in the healthcare sector, continues to capture investor interest with its impressive growth metrics and promising future outlook. With a market capitalization..

Gilead Sciences (GILD) Stock Analysis: A Healthcare Giant with a Robust 5% Potential Upside

Gilead Sciences, Inc. (NASDAQ: GILD) stands as a formidable player in the healthcare sector, specifically within the drug manufacturing industry. Headquartered in Foster City, California, Gilead has carved out a..

Insulet Corporation (PODD) Stock Analysis: Exploring a Promising 43.71% Upside in the Medical Devices Sector

Insulet Corporation (PODD), a prominent player in the healthcare sector, specifically within the medical devices industry, is drawing significant interest from investors due to its innovative insulin delivery systems. Headquartered..

Doximity, Inc. (DOCS) Stock Analysis: Navigating a 62.87% Upside Potential in Health Information Services

Doximity, Inc. (NYSE: DOCS) stands as a prominent name in the healthcare sector, particularly within the health information services industry. Known for its digital platform tailored to medical professionals, Doximity..

Globus Medical, Inc. (GMED) Stock Analysis: A Healthcare Innovator with 14.75% Upside Potential

Globus Medical, Inc. (NYSE: GMED), a leader in the healthcare sector, is attracting investor attention with its robust growth potential and innovative solutions for musculoskeletal disorders. Headquartered in Audubon, Pennsylvania,..

Vertex Pharmaceuticals (VRTX) Stock Analysis: Poised for Growth with a 7.27% Upside Potential

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a powerhouse in the biotechnology sector, continues to make waves with its innovative approach to addressing severe diseases. With a market capitalization of $126.21 billion,..

Universal Health Services, Inc. (UHS) Stock Analysis: Exploring a 22% Potential Upside

In the competitive landscape of healthcare, Universal Health Services, Inc. (NYSE: UHS) stands out as a formidable player with a promising outlook for investors. Headquartered in King of Prussia, Pennsylvania,..

Insmed Incorporated (INSM): Investor Outlook Reveals a Promising 42% Upside

Insmed Incorporated (NASDAQ: INSM), a biotechnology firm headquartered in Bridgewater, New Jersey, is making waves in the healthcare sector with a notable potential upside of 42.32%. Specializing in developing therapies..

DexCom, Inc. (DXCM) Stock Analysis: 16.91% Potential Upside Amid Robust Growth Metrics

DexCom, Inc. (NASDAQ: DXCM), a leader in the healthcare sector’s medical devices industry, has been revolutionizing diabetes management through its cutting-edge continuous glucose monitoring (CGM) systems. With a current market..

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: An 84.90% Revenue Surge and 37.27% Upside Potential

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a pioneering entity in RNA interference therapeutics, has been generating buzz in the biotechnology sector with its impressive revenue growth and significant upside potential. Based..

Agilent Technologies, Inc. (A) Stock Analysis: Exploring a 34.15% Upside Potential in the Healthcare Sector

Agilent Technologies, Inc. (NYSE: A) stands as a formidable player in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of $34.41 billion, Agilent is..

Teva Pharmaceutical Industries (TEVA) Stock Analysis: A 12.36% Upside Beckons in Healthcare Innovation

Teva Pharmaceutical Industries Limited (NYSE: TEVA), a stalwart in the healthcare sector, has long stood at the forefront of the drug manufacturing industry, particularly specializing in generic and specialty medicines...

Hologic, Inc. (HOLX) Stock Analysis: Navigating Growth in the Medical Instruments Sector

Hologic, Inc. (NASDAQ: HOLX) stands at the forefront of the healthcare sector, specializing in medical instruments and supplies with a primary focus on women’s health. With a market cap of..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds